PredicineCARE™, provides critical insights into treatment efficacy & resistance mechanisms. This study, recently published in Nature Medicine, underscores PredicineCARE™'s pivotal role in supporting Incyte's Phase II basket trial. View publication he…
157 followers
161 followers
RT @cancer_evolve: DRUG TARGETS: in a phase 2 basket study, the FGFR inhibitor pemigatinib delivered ORR 27% and 9% for tumours with FGFR f…
3,048 followers
Pan-#cancer effectiveness of #FGFR #inhibitors But only if you comprehensively test for FGFR plus co-mutations in all solid tumours. That is easier to do if you are already running large #Dx gene panels for all your tests, as we do @NorthThamesGMS http…
378 followers
DRUG TARGETS: in a phase 2 basket study, the FGFR inhibitor pemigatinib delivered ORR 27% and 9% for tumours with FGFR fusions and activating mutations, respectively; comutation of TP53 or BAP1 conferred resistance or enhanced sensitivity, respectively.…